Payment overview · 2025
General Payments
$133.05
7 reported records · 4 companies
Healthcare provider profile · identity verified
David E Spivey, MD
Allopathic & Osteopathic Physicians|Family Medicine · GARNER, NC · NPI 1467413054
Verified facts
What the public records show
CMS Open Payments records show David E Spivey, MD received $133.05 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.91 | 38.3% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$40.81 | 30.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.10 | 20.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.23 | 10.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $133.05 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 194 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
194 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 560 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 559 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 373 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 116 |
| Metformin Hcl | Metformin Hcl | 318 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 84 |
| Gabapentin | Gabapentin | 290 | 80 |
| Omeprazole | Omeprazole | 259 | 71 |
| Alprazolam | Alprazolam | 247 | 57 |
| Lisinopril | Lisinopril | 238 | 68 |
| Sertraline Hcl | Sertraline Hcl | 214 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 213 | 41 |
| Losartan Potassium | Losartan Potassium | 206 | 66 |
| Simvastatin | Simvastatin | 205 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 61 |
| Meloxicam | Meloxicam | 198 | 61 |
| Tramadol Hcl | Tramadol Hcl | 196 | 43 |
| Jardiance | Empagliflozin | 194 | 42 |
| Eliquis | Apixaban | 190 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 35 |
| Trazodone Hcl | Trazodone Hcl | 168 | 46 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 166 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 164 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 45 |
| Ezetimibe | Ezetimibe | 157 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 42 |
| Celecoxib | Celecoxib | 142 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 54 |
| Bupropion Xl | Bupropion Hcl | 130 | 28 |
| Glimepiride | Glimepiride | 128 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 32 |
| Ozempic | Semaglutide | 123 | 18 |
| Mirtazapine | Mirtazapine | 117 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 28 |
| Clonazepam | Clonazepam | 111 | 23 |
| Famotidine | Famotidine | 108 | 25 |
| Januvia | Sitagliptin Phosphate | 98 | 16 |
| Montelukast Sodium | Montelukast Sodium | 97 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 21 |
| Metformin Hcl Er | Metformin Hcl | 92 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 28 |
| Potassium Chloride | Potassium Chloride | 89 | 29 |
| Furosemide | Furosemide | 88 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 18 |
| Allopurinol | Allopurinol | 79 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 18 |
| Spironolactone | Spironolactone | 70 | 18 |
| Glipizide Er | Glipizide | 69 | 16 |
| Diazepam | Diazepam | 68 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 20 |
| Lorazepam | Lorazepam | 66 | 17 |
| Carvedilol | Carvedilol | 65 | 18 |
| Cefdinir | Cefdinir | 59 | 48 |
| Benazepril Hcl | Benazepril Hcl | 54 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 11 |
| Warfarin Sodium | Warfarin Sodium | 52 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 15 |
| Pregabalin | Pregabalin | 50 | 12 |
| Temazepam | Temazepam | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 11 |
| Etodolac | Etodolac | 49 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 49 | suppressed |
| Mupirocin | Mupirocin | 48 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 43 |
| Ramipril | Ramipril | 46 | 12 |
| Prednisone | Prednisone | 45 | 15 |
| Bumetanide | Bumetanide | 44 | 12 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Nystatin | Nystatin | 44 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Estradiol | Estradiol | 41 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Glipizide | Glipizide | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 33 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Brilinta | Ticagrelor | 30 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Atenolol | Atenolol | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Cephalexin | Cephalexin | 27 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | 14 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $133.05 · 7 records | Amgen Inc. | EVENITY, INCEPTIV, JARDIANCE, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error